Crude Edible Fig (*Ficus carica*) Leaf Extract Prevents
Diethylstilbestrol (DES)-Induced DNA Strand Breaks in Single-Cell Gel Electrophoresis (SCGE)/Comet Assay: Literature Review and Pilot Study

Alrena V Lightbourn*, Ronald D Thomas
Basic & Pharmaceutical Sciences Division, College of Pharmacy & Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA

Abstract

Fig (*Ficus carica*) trees are among the oldest plants on earth. The chemopreventive properties of constituent polyphenols and fiber that implicate figs in having a functional role in averting cancer have not been fully elucidated. We therefore hypothesized that fig leaf extract would inhibit (or attenuate) DES-induced DNA single-strand breakage in MCF10A human breast epithelial cells. To test this hypothesis, MCF10A cells were treated with DES (1, 10, 100 μM), crude fig leaf extract (5, 10, 15 μL), or concomitant doses of DES (100 μM)/fig leaf extract (5, 10, 15 μL). The cells were analyzed for DNA strand breakage using the SCGE/COMET assay with mean olive tail moment as a marker of DNA damage. DES induced DNA strand breaks at all treatment levels compared to DMSO and non-treatment controls. DES at concentrations of 1, 10, and 100 μM produced mean olive tail moments of 1.2082 (177.6%), 1.2702 (186.7%), and 1.1275 (165.7%), respectively, which were statistically significantly (p<0.05) higher than the DMSO control value (0.6803). Exposure to fig leaf extract produced no DNA damage. Rather, a desirable dose-dependent reduction in DES-induced DNA strand breaks was observed. Composite treatment of MCF10A cells with DES and fig leaf extract attenuated DES-induced DNA strand breaks. Taken together, these results suggest a potential mechanism for cancer chemoprevention. Additional studies are necessary to identify relevant active ingredients, confirm the mechanism of action, and further elucidate the therapeutic potential of fig leaf extract for early-stage breast cancer chemoprevention.

Keywords

Diethylstilbestrol; Fig; *Ficus carica*; DNA damage; Strand break; SCGE; COMET assay; MCF10A; Breast cancer

*Corresponding author: Alrena V. Lightbourn, Basic & Pharmaceutical Sciences Division, College of Pharmacy & Pharmaceutical Sciences, Florida A&M University, 2074 Midyette Rd, Suite 117, Tallahassee, FL, USA, Tel: 7812858693; lighbournal@yahoo.com.

Conflict of Interest
The author knows of no financial interest or any conflict of interest relative to this article.
Introduction

Cancer, ranked the second leading cause of mortality in the United States [1] and Florida [2], is further segregated to attribute to breast cancer the designation of No. 1 cause of death among women [3,4]. The most recent global cancer statistics (September 12, 2018) point out an escalating pattern in cancer incidence and mortality based on 36 types of cancer measured in 185 countries of the world. Roughly 18.1 million new cases and 9.6 million cancer deaths are expected globally in 2018 alone. Of these cases, the incidence and mortality of cancer in the Americas (North, South and Central America, and the Caribbean), is estimated at 21.0% (~3.8 million) and 14.4% (~1.4 million) cases, respectively. The incidence of breast cancer ranks second (11.6%) and deaths fifth (6.6%) among the most commonly diagnosed cancers (lung, breast, colorectal, stomach, liver and prostate) in both sexes. Female victims of cancer represent 24.2% (8.6 million) of new cases and roughly 15.0% (4.2 million) of deaths [5]. Overall, from 2017-2018, in situ cases are the primary form (28%) of breast cancer in women between 50-69 years old; invasive cases prevail (27%) between 60-69 years old; and deaths are most prevalent (27%) ≥80 years old [1,6,7].

Disparities exist in the incidence of female breast cancer based on data from 1975-2014, which indicate a higher rate of smaller (<2.0 cm) tumors per 100,000 Blacks compared to White females with larger tumors (2.0 – 4.9 cm). A closer review of the overall death toll among Black females with breast cancer from 1975-2015 revealed a more subtle overall decline in mortality than the more prominent reduction in mortality rates noted among White females. In 2015, Black women experienced ~39% higher death rates (29.5 per 100,000) than Whites (20.8 per 100,000), a difference possibly attributed to differences in associated risk factors (e.g., socioeconomic conditions, comorbidities such as obesity. The 5-year survival rate was a meager 9% following diagnosis [6].

Early intervention is imperative for increasing the chance of recovery from treatment of breast cancer. Ductal or lobular malignancies may initially be detected as a lump or other visible change in the morphology of the breast. General risk factors that increase the chance of developing breast cancer may include: family history of the disease in immediate female family members; personal history of benign breast tumor; personal history of invasive, in situ or lobular malignancy; dense mammary tissue; inherited genetic mutations of breast cancer genes (e.g., BRCA1, BRCA2); early onset of menarche; older age of first birth; exposure to radiation; obesity; alcohol consumption; sedentary lifestyle; hormonal treatment of menopause [8], and high fat consumption [9]. Current clinical interventions for breast cancer include screening measures such as: clinical breast exam; screening mammography; breast tomosynthesis; breast ultrasound; breast MRI [10]; thermography; tissue sampling via fine-needle aspiration, nipple aspiration, or ductal lavage; chemotherapy; adjuvant therapy; surgical removal of the breast or relevant area of tissue [8]. An annual mammogram is recommended for women ≥40 years old, and certain high-risk (e.g., history of breast cancer in immediate family; genetic predisposition) subgroups of women ≥30 years old may be subject to varying combinations of mammography, MRI or ultrasound procedures annually [6]. Due to the invasive nature of some existing screening methods, as well as the increased risk of cancer growth from radiation exposure, alternative approaches are needed both to prevent and treat female breast cancer. Since the 1990s, alternative medicine has helped to
bridge gaps in therapy left by modern pharmaceuticals [11,12], which in part, have been unable to cure long term conditions (e.g., bronchitis, arthritis, rheumatism, heart disease, back pain, high blood pressure, ulcers, etc.) and sometimes chronic degenerative diseases of aging [13]. Hitherto, a wide array of studies has demonstrated an inverse correlation between cancer incidence and the intake of fruits and vegetables [8,14].

Edible fig (Ficus carica L.) trees are dicotyledonous, perennial plants belonging to the Moraceae (Mulberry) family. Native to Egypt or Western Asia, fig trees were introduced into Middle Eastern and European civilizations, as well as various regions of the United States: New England (MA); Mid-Atlantic (NY, PA); South Atlantic (FL, NC, SC, VA, DC); East South Central (AL, MS, TN); West South Central (LA, TX); and Pacific (CA) [15–19]. The United States, Turkey, Greece and Spain are among the largest producers of fig in the world [15]. In the U.S. consumption of figs is measured both by imports and exports of this commodity. Approximately 27 million pounds of fresh or dried fig valued at roughly $47 million was imported from 2017-2018. National agricultural statistics for the same period showed that 6.9 million pounds of fig were exported for a new gain of almost $14 million [17,18]. Production in the state of California accounts for 98% of U.S.-grown figs [20], which may be incorporated into fig paste, concentrate, powder, or nuggets, or simply diced or sliced [15,21].

Medicinal [22,23], folkloric [24] and biblical [25] uses of figs have been documented for centuries. Figs are fat-free, low in sodium, and cholesterol-free [15]. Figs are a nutrient-rich dietary source of natural sugar, vitamins (A, B1, B2, B3 and C), minerals (potassium, zinc, magnesium, iron, nitrogen, calcium, phosphorus), fiber and antioxidants (polyphenols) [15,26]. Non-nutrient components found in figs include: benzaldehyde and coumarins (i.e., angelicin, marmesin, psoralen, umbelliferone, and bergapten) [15]. Constituents of fig leaf include: phytosterols such as beta-sitosterol and taraxasterol; and furanocoumarins such as: psoralen and bergapten, [15,23,27]. Latex (a white milk) may be obtained from fig fruit, twigs, as well as from fig leaves. Ficin, a proteolytic enzyme capable of dissolving growths such as corns and warts [22–24], is found in fig leaves.

The biological and ecological importance of the fig tree cannot be overlooked. Wild fig is revered as a “keystone fruit,” meaning that it is essential for the survival of other plants and animals [28]. The fig plant is described as a remedy for at least forty different health conditions and its health benefits are associated with cardiovascular, respiratory, digestive, urinary, integumentary, muscular, immune, hepatic, reproductive and endocrine systems of the human body [27]. Medicinal and biological uses of fig leaves, fruit, roots, or bark include its application as follows: aphrodisiac for sterility, endurance, or erectile dysfunction [29,30], laxative [22], relief for sores and sore throat [22], antibacterial, antiviral, antifungal, anti-diabetes [22,31], antioxidant, anti-cancer, hepatoprotective, hypoglycemic, hypolipidemic, anti-HSV, antipyretic, anti-tuberculosis, nematicidal, anti-spasmodic, anti-platelet, anti-helmintic, and anti-mutagenic activity [22,29,32–34]. Figs have also been found to lower the risk of Alzheimer’s disease [35], treat piles (hemorrhoids), and restore skin and hair health [36]. Fig is a folkloric emmenagogue, which can stimulate menstrual flow in the absence of a regular period (amenorrhea) [24]. In ancient biblical days, it was known as the “forbidden fruit” in the Garden of Eden [37], and later King Solomon is said to
have applied fig juice to boils [24]. Because of its broad reach, the fig plant is thought to hold great promise for the future of phytomedicine.

Although the mechanisms of fig action on human health have not been fully elucidated, the ubiquity of polyphenols and its high flavonoid content suggest a strong anticancer potential. These substances, common to citrus fruits, are known for protections afforded through: exertion of antioxidant effects; enhancement of the body’s innate detoxification system via cytochrome P450 (CYP450) monoxygenase system; and regulation of enzymes produced by cancer cells [13,15]. Known health benefits attributed to figs include: weight loss; lowering cholesterol; prevention of constipation, heart disease, colon cancer, hypertension, macular degeneration; diabetes control; throat pain relief; urinary calcium loss; venereal disease; strengthens bones; bronchitis; aphrodisiac for sexual dysfunction.

Issues surrounding the treatment of breast cancer are challenging and controversial. Early detection of breast cancer is made possible through the administration of a low-dose x-ray (mammogram), which for many years was recognized as the only screening tool proven to decrease breast cancer mortality rates [10,6]. The Radiological Society of North America (RSNA) reported on December 1, 2009 that exposure to therapeutic, low-dose radiation during annual mammograms, as well as repeated exposures, may actually enhance the risk developing cancer in non-diagnosed individuals who may have a familial or genetic predisposition [10]. Odds ratios among high-risk subjects were 1.5× higher than that observed in similar high-risk females devoid of radiological exposure [10,38,39]. On considering breast screening [40–43], several researchers found that supplementing the mammogram with tomosynthesis dramatically enhances the detection of breast cancer [42,43]. Similarly, RSNA [10] reports that more breast cancers are detected with combined digital measures than with any one alone [44]. Commonly observed comorbidities have also been reported among breast cancer survivors [45]. In other postoperative uses of adjuvant radiotherapy to eradicate residual cancer cells, radiotherapy was found to reduce breast cancer mortality, but rather increase cardiovascular disease and lung cancer in the United States [46] and in Germany [47]. Death from heart disease after longterm radiotherapy for breast cancer was also observed by Bouillon and associates [48]. It is possible that the medicinal properties of figs in almost every system of the human body may attenuate breast cancer as well as other comorbidities.

To elicit their protective effects, phytochemicals interact with a variety extracellular structural components as well as intracellular molecules, pathways and organelles, thereby counteracting the development of cancer and non-cancer, chronic diseases in the human body. Cancer is a disease commonly characterized by genetic mutation, unregulated cellular proliferation, and aberrant tumor growth and development. The relevance of plant chemicals in cancer prevention is of particular interest to researchers who recognize the importance of identifying specific areas of the multistage process of carcinogenesis where they are most effective. Mammary cancer is also a multi-stage process (Figure 1) that can be induced by chemicals, radiation, viruses, or genetic factors [49]. Absent the timely detoxification and elimination of procarcinogenic chemicals from the body, subsequent absorption and metabolism of cancer-causing agents can lead to the formation of reactive metabolites that may impose more deleterious effects than the parent compound from which they were
derived. In recognition of the critical interface between phytochemicals and the process of carcinogenesis, Michael Sporn coined the term ‘chemoprevention’ [50,51] to describe substances capable of inhibiting, reversing or retarding tumorigenesis [14].

The term ‘chemoprevention’ also embodies the two major functional classes of chemopreventive agents: those that either block procarcinogenic insult of normal cells (e.g., ellagic acid, indole-3-carbinol and flavinoids) and those that suppress or retard the transformation of initiated cells into neoplastic lesions (beta-carotene, curcumin, genistein, resveratrol and capsaicin) [14]. However, based on these findings, there remained a gap in the discovery of agents capable of inhibiting, reversing, or retarding that rate-limiting, rapid, irreversible first stage of carcinogenesis (i.e., initiation) through which heritable genetic changes may occur. It is in the initiation stage of carcinogenesis that physical interaction of a procarcinogenic, promutagenic substance with DNA leads to DNA damage [52]. Direct action of electrophilic carcinogens can produce highly reactive, nucleophilic metabolites that covalently bind to DNA, causing DNA-adduct formation, and exerting genotoxic effects. Interactions with reactive oxygen, nitrogen or sulfur species may also be genotoxic [52,14].

At the time of this research, the mechanism of natural products derived from plants, and having chemopreventive properties, had not been fully elucidated. Moreover the focus of understanding mechanisms of action of chemopreventive substance such as the Ficus carica leaf extract we studied relative to malignant neoplasms versus benign conditions was still in its infancy.

Diethylstilbestrol has generally been classified as a non-genotoxic (epigenetic) chemical carcinogen with a hormonal mode of action [52]. Epigenetic carcinogens are sad to exert their effects via mechanisms that “[do not involve] DNA binding, damage, or interaction of the chemical or its metabolites with DNA” [52]. In the wake of these controversies, we hypothesized that fig leaf extract would abrogate or attenuate DES-induced DNA stand breaks. Using the single-cell gel electrophoresis and the comet assay, the objectives of the associated pilot study towards realizing this goal led us to: (1) establish baseline deoxyribonucleic acid (DNA) damage in untreated human breast epithelial cells; (2) determine the effect of fig leaf extract alone on MCF10A cells; (3) assess the integrity of DNA following carcinogen exposure of MCF10-A cells to DES, or its metabolite, DESQ; and (4) assess the ability of fig leaf extract to eradicate DES-induced nuclear effects in MCF10A cells. These preliminary data form the basis of our suggestion that fig leaf extract demonstrates both chemoprotective and chemopreventive properties. Our findings not only warrant reconsideration of DES as a genotoxic agent, but also provide evidence for a phytochemical intervention directly targeting carcinogenesis stage 1 (initiation). The insights from this study fuel the need for more breast cancer research involving this agent, and show promise for the future clinical utility of Ficus carica leaf extract for combating early-stage breast cancer development.

Materials and Methods

Cells and chemicals

Immortalized, non-transformed, non-tumorigenic (benign) human breast epithelial (MCF10A) cells derived from a 36 year-old, Caucasian female with fibrocystic breast...
disease were purchased from American Type Cell Culture Collection (ATCC), Rockville, MD). Chemicals used included Dulbecco’s Modified Eagle’s Medium (DMEM), streptomycin, phosphate-buffered solution (PBS), and trypsin, and were purchased with disposable supplies purchased from Sigma Chemical Company (St. Louis, MO). All refrigerated solutions were brought to room temperature before use.

Cell culture

Human breast epithelial (MCF10A) cells were sub-cultured twice weekly in serum-free Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with streptomycin. Incubator settings were 5% CO₂, 95% air at 37 °C, and 100% humidity. The cells were maintained as exponentially-growing monolayers until confluency was achieved. The cells were washed in PBS, trypsinized, and resuspended in DMEM before treatment.

Aqueous extraction of the leaves of *Ficus carica*

Fig leaf extract was prepared and refrigerated for future use in research experiments. According to lab protocol, fig leaves were weighed and twice-boiled in water for 30 minutes and the extract vacuum filtered. The extract was treated with 3 ml of 1% HCl per gram of leaf, centrifuged at 3000 rpm for 10 minutes, and the supernatant filtered by vacuum filtration. The extract was concentrated to 50 ml and the pH adjusted to 7.4.

Analysis of DNA strand breaks by COMET assay

Single-cell gel electrophoresis (SCGE) or the ‘comet assay’ is a rapid, sensitive, and reliable biochemical technique (Figure 2) for identifying and quantify DNA damage in individual mammalian cells. In the current study, the comet assay was used to detect varying levels of carcinogen-induced DNA fragmentation in normal breast epithelial (MCF10A) cells. The cells were exposed to varying doses of DES dissolved in dimethyl sulfoxide (DMSO), different volumes of fig extract, or a combination of both for 6 hours. Next, MCF10A cells mixed with low-melting point agarose were coated onto frosted slides. Following overnight incubation in an alkaline lysis buffer, the cells underwent electrophoresis in a fresh alkaline rinse solution at 25V/300mA for 30 minutes. The cells were then neutralized and air-dried in preparation for microscopy. Slides were visualized at 20x magnification using propidium iodide as the fluorochrome. The olive tail moment (OTM) was calculated for 40 randomly selected cells from each sample (n=3) using Kinetic® Imaging Komet software.

Phase contrast microscopy

The growth of cultures of MCF10A cells and comets resulting from chemical treatment were observed by phase-contrast microscopy using a Zeiss fluorescence microscope. DNA stained with propidium iodide was filtered with green-light (excitation ≈546 nm). Where available, photographs of comets were taken to establish DNA damage and/or repair, and to visualize the migration of tail fragments, which form the pattern of a comet during gel electrophoresis.
Statistical analysis

The quantitative data (Table 1) represent triplicate assays (mean ± SEM) of samples obtained from independent, *in vitro* experiments. Of the 34 parameters measured, olive tail moment (OTM) – the product of percent tail DNA and the distance between the centers of gravity in the head and the tail [53], was selected. A total of 2000 comets from 51 slides were assessed. SAS® software was used to perform statistical analyses of mean olive tail moment, by treatment group. The distribution of the continuous variable (“treatment”) was investigated using the PROC UNIVARIATE procedure. For all treatment groups, there existed a statistically significant difference between treatment means and zero (p<.0001, denoted ‘***’). Differences between specific treatment groups determined by one-way analysis of variance (ANOVA) were further assessed using the Tukey, multiple comparisons, post-hoc test. Statistical significance was set at an alpha level of p<.05 (denoted ‘*’). Where appropriate and convenient, some graphs were sketched in Microsoft Excel.

Results

Sensitivity of COMET assay

The SCGE/COMET assay is a sensitive, non-radiometric procedure. This technique was effective in assessing DES-induced DNA damage in benign human breast epithelial (MCF10A) cells as well as measuring the extent of nuclear insult imposed on MCF10A by environmental estrogens and their metabolites. The protective effects of fig leaf extract in mediating these genotoxic effects were measurable following 6 hours of carcinogen treatment. Microliter quantities of fig leaf extract were also sufficiently potent to evoke cellular changes resulting in DNA repair that was detectable by COMET analysis. Morphological changes in cell structure, particularly intact or disrupted DNA, were visually observed by dark-field microscope (Figure 3).

Analysis of means

Based on the MEANS procedure in SAS®, the null hypothesis that the average olive tail moment (OTM) for 17 different treatment groups is equal to zero was rejected (p<.00005), versus the alternative hypothesis that individual treatment means are not equal to zero. We conclude that the average OTM is different for each type of treatment, indicating that the true mean is greater than zero. This conclusion was also confirmed via the ANOVA procedure in SAS®. Data are presented as Mean ± SEM.

Baseline DNA damage in untreated MCF10A cells—To measure the occurrence of baseline (spontaneous) DNA stand breaks within human epithelial breast cells, untreated MCF10A cells incubated in growth medium were monitored for comets. The average olive tail moment for comets scored in 120 untreated MCF10A cells was 0.81 ±0.09 (p<.00005). A score above zero in untreated cells confirms that damage (and repair) has spontaneously occurred to DNA within these cells, which is consistent with self-regulated endogenous processes of homeostasis.

Nuclear cryoprotection in DMSO-treated MCF10A cells—Dimethyl sulfoxide is routinely added to mammalian cells to preserve and protect proteins from denaturing during
The effect of cryopreservation on DNA integrity within human epithelial breast (MCF10A) cells suspended in DMSO was monitored for comets. The average olive tail moment for comets scored in 120 DMSO-treated MCF10A cells was 0.68 ± 0.06 (p<0.0005). This score attests to the added benefit of DMSO, as 16.4% less DNA damage resulted following DMSO treatment compared to untreated controls (0-81 ± 0.09).

**Effect of DES on MCF10A cells**—DES (the parent compound) induced cell death in MCF10A cells, evidenced by the uptake of propidium iodide by cellular nuclei. Moreover, administration of DES at a concentration of 1 μM (1.21 ± 0.25), 10 μM (1.27 ± 1.14), or 100 μM (1.13 ± 0.10) had the greatest impact in OTM (p<0.00005) than all other treatment groups. Although the mean OTM increased in a linear fashion at the lower doses of DES, a slightly lower response is seen at the high dose level. These average scores were respectively 148.7%, 156.3%, and 138.7% above untreated control cell levels (0-81 ± 0.09). Compared to DMSO controls (0-68 ± 0.07), the mean OTM was 178%, 187% and 166% higher in respective DES treatment groups. The dose of DES with the lowest amount of DNA damage was DES 100 μM for this treatment group.

**Effect of DES-Quinone on MCF10A cells**—The extent to which DESQ (a metabolite of DES) induced cell death in MCF10A cells was less than that observed for all doses of DES-treated cells. Administration of DESQ at a concentration of 1 μM (0.87 ± 0.09), but not at concentrations of 10 μM (0.59 ± 0.06), or 100 μM (0.62 ± 0.05), significantly increased OTM (107.4%) above untreated control values (0-81 ± 0.09). The latter dose levels were less effective (72.3% and 76.0%, respectively) in causing DNA strand breaks. The reduction seen in mean OTM with increasing dose levels of DESQ was not linear, although the DES metabolite was notably less effective in causing strand breaks than the parent compound. These average scores were respectively 128%, 86%, and 91% of DMSO control values (0-68 ± 0.07). The dose of DESQ with the lowest amount of DNA damage was DESQ 10 μM for this treatment group.

**Effect of fig leaf extract on MCF10A cells**—Aqueous fig leaf extract administered alone attenuated DNA damage at all study volumes (5 μL, 10 μL, and 15 μL). Mean OTM values were 0.71 ± 0.09 (86.9%), 0.69 ± 0.06 (84.3%), and 0.79 ± 0.08 (96.7%), respectively when compared to untreated controls (0-81±0.09). Compared to the DMSO-controls (0-68 ± 0.07), dosing with 5 μL, 10 μL, or 15 μL fig leaf extract elicited roughly comparable differences in average OTM (104%, 101% and 116%, respectively) The volume of fig leaf extract producing the lowest amount of DNA damage was Fig 10 μL for this treatment group.

**Combined effects of DES (Parent Compound) and fig leaf extract on MCF10A cells**—As above, DES administered alone (1, 10, or 100 μM) produced OTMs of 1.21, 1.27, and 1.13, respectively. The effect of high-dose DES (100 μM) was offset by administration of fig leaf extract in volumes of 5 μL (1.01 ± 0.10), 10 μL (0.52 ± 0.04), or 15 μL (0.63 ± 0.07), indicating generally tangible reductions in DNA damage and fig leaf extract-mediated protection at higher doses. Tow volume extract only marginally reduced the amount of DNA strand breaks elicited by high dose DES (Table 2).
OTMs resulting from combined treatments were 124.7% (DES 100-Fig5), 63.5% (DES100-Fig10), and 77.6% (DES100-Fig15) of untreated control levels, and 149% (DES100-Fig5), 76% (DES100-Fig10) and 93% (DES100-Fig15) of DMSO control values. With the exception of the DES100-Fig 5 group, the reductions in DNA damage (comet formation, DNA strand breaks) were substantial. Tow dose fig marginally attenuated DNA strand breaks caused by 100 μM DES. However, doubling or tripling the volume of fig extract significantly abrogated DES-induced DNA damage. The combination of DES 100 μM with Fig 10 μL produced the least amount of DNA damage observed by comet assay for this treatment group.

**Combined effects of DESQ (Metabolite) and fig leaf extract on MCF10A cells**—Following induction of DNA damage by pre-exposure to the metabolite of a carcinogenic xenoestrogen, administration of fig leaf extract resulted in a reversal of these effects, below the level of DNA damage observed in untreated controls. Mean OTM following co-administration of DESQ (10 μM) with increasing volumes of fig leaf extract were 0.66 ± 0.06 (5 μL), 0.715 ± 0.07 (10 μL), and 0.59 ± 0.06 (15 μL), respectively. These values were respectively 81.6%, 107.8%, and 82.2% compared to untreated controls (0-81 ± 0.09), versus 98%, 105% and 86% when compared to DMSO controls (0-68 ± 0.07). High volume fig leaf extract (15 μL) was most successful in inhibiting DES-Q (10 μM)-induced DNA strand breakage.

**Multiple comparisons of OTMs across treatment groups in MCF10A cells**—In ANOVA posthoc multiple comparisons of OTM means, Tukey’s studentized range test identified the following groups as being statistically significantly different from each other:

- DES 1 μM was significantly different from: DMSO control; Fig 5; Fig 10; DES100-Fig10; DESQ-10; DESQ-100; DESQ10-Fig5; DESQ10-Fig10; and DESQ10-Fig15 treatment groups (p<.05).
- DES 10 μM was significantly different from: DMSO control; Fig5; Fig10; DES100-Fig10; DES100-Fig15; DESQ-10; DESQ-100; DESQ10-Fig5; DESQ10-Fig10; DESQ10-Fig15 (p<.05).
- DES-100 μM was significantly different from: DES100-Fig10; DESQ-10; DESQ-100; and DESQ10-Fig15 (p<.05).
- DES-100 μM-Fig 5 μL was significantly different from: DES 100-Fig10 (p<.05).

**Discussion**

This *in vitro* pilot study was uniquely designed to investigate the utility of *Ficus carica L.* (fig) leaf extract in lowering the risk for human breast cancer. We hypothesized that fig leaf extract would inhibit DES-induced DNA single strand breakage in normal breast epithelial (MCF10A) cells at a time when the anti-mutagenic potential of figs had only been suggested [54] but not exhaustively researched in the open literature. The pilot study affirmed our hypothesis, providing the first such preliminary experimental data that fig leaf extract attenuates DES-induced DNA strand breaks in MCF10A human breast epithelial cells during the initial stage of cancer development.
In the multi-step model of carcinogenesis, damage to nuclear deoxyribonucleic acid (DNA) is an essential initiating event for the production of genetic lesions that lead to instability of the genome. Exposure to carcinogenic agents may cause mutations and alter DNA repair and cell cycle control genes. Diethylstilbestrol (DES) is an example of a synthetic estrogenic hormone that is toxicologically characterized as a complete carcinogen. It is known to induce and promote the development of malignant tumors in human breast epithelial cells as well as rodent models. DES is actively biotransformed by cytochrome P450 drug-metabolizing enzymes into its primary metabolically active intermediate, DES-4,4’-quinone (DESQ). The interaction of DESQ with DNA results in the formation of DNA adducts and strand breaks [55]. In the absence of repair, alterations in genes regulating these processes may cause normal cells to be transformed into malignant phenotypes. Replication of these cells can promote the progression of tumorigenesis. The current pilot study showed a stronger potency of the parent compound, DES, than its metabolite, DESQ, where induction of DNA damage was concerned. The destructive effects elicited by the parent compound were consistently more pronounced than those of the metabolite and/or phytochemicals used for chemoprevention. This paradox is interesting because of the three processes commonly implicated in the initiation of cancer in a single cell: metabolism, DNA repair, and cell proliferation [56]. DESQ may be metabolized to either the O- or S- reactive nucleophile (Figure 4) and both are capable to inducing DNA damage [55]. This current finding is also controversial because it intimates that either metabolism is not mandatory for DES to produce genotoxic effects in human breast epithelial cells, or like the traditional view of longterm (≈30 years) development of cancer, the graded effects of low doses of carcinogens over a long time still amount to the same outcome of neoplasm development. Alternatively, it is plausible to consider the presence of a discriminate mechanism whereby DES binds with high affinity to mitogenic ER-alpha, while the action of DESQ is mediated by a ‘deceptively protective’ mechanism at ER-beta [57–61]. Further research is necessary to elucidate these matters.

In this study, low level, DNA damage spontaneously generated within human breast epithelial (MCF10A) cells without exposure to hazardous substances, or with the advantage of exposure to the cryoprotective agent, DMSO. This finding is consistent with limited evidence suggesting endogenous estrogen under certain conditions can itself serve as an initiator of DNA damage [62,63] and increases risk of breast cancer in premenopausal and post-menopausal women [64]. Shifting the microenvironment of cells from estrogen-responsive breast tissue by addition of micoliter quantities of Ficus carica leaf extract produced minimal DNA damage relative to experimental controls, implicating its benefits in suppressing tumor cell transformation [65], a potential preference for ER-beta [66], and the well-established observation that a much weaker estrogenic effect is characteristic of phytoestrogens (Figure 5) [66]. These findings also suggest that the fig leaf extract employed in these experiments was roughly as safe as controls, permitting differentiation of its biological activity when used in combination with carcinogens. It is likely that the high phenolic content of fig leaves and the oxygen-scavenging, protective, healing properties of Ficus species [67,68] acts in conjunction with routine innate repair mechanisms of homeostasis within human breast epithelial cells that are benign but capable of activation
In studies by Zhang and associates [69], treatment with *Ficus carica* leaf extract did not compromise the viability of MCF10A cells.

The mechanism of action of DES, its metabolites or analogs is controversial and efforts to elucidate same relative to carcinogenesis continue to emerge. Due to structural similarities, the presence of a phenolic A-ring is critical to receptor binding and estrogenic activity at the estrogen receptor, but not other steroid receptors [9]. Compared to DES, which has two phenol groups at 3-OH and 17-OH, 12.1 Å apart, the distance between these moieties in estradiol is 10.9 Å [9]. DES metabolites or analogs that retain these characteristics exhibit significant activity at the ER, but estrogenic activity is abolished without them [9]. DES and estradiol share similar binding affinities ($K_a$ of $1.0 \times 10^{10} \pm 0.8$ and $1.5 \times 10^{10} \pm 0.3$, respectively) for the estrogen receptor. DES binds to both ER-alpha and ER-beta [70], while most phytoestrogens exert their anti-estrogenic effects through ER-beta [60,59]. However, whether the carcinogenic potential of the molecule is fueled by the parent compound, or by an oxidative metabolite, has long been unclear [71]. Past research has show DESQ to have tangibly greater activity than DES under certain conditions [72].

In the present study evaluating the carcinogenic properties of DES, it was DES (the parent compound) whose biological activity produced the greater quantity of DNA strand breaks, rather than here weaker DESQ, one of its many reactive oxidative metabolites [72,73]. Here, the necessity for metabolism of this procarcinogen to produce genomic instability was perhaps not the sole determinant of the genotoxic response observed. Both DES and DESQ are able to cross the lipophilic cytoplasmic membrane to enter the cytosol, prior to being translocated into the nucleus for further binding to the estrogen receptor (ER). Rapid metabolism of DESQ by the cytochrome P450 (CYP450) monooxygenase system also provokes a weaker physiological response in affected cells. DESQ binds irreversibly and with only a fraction of the binding affinity of DES, providing a weaker yet persistent stimulus to the ER [74]. DES and DESQ are differentially induce estrogenic and carcinogenic effects, albeit with vastly different rates. The longer stay and persistent low action of DESQ at the ER increases the probability of genomic interactions and may eventually contribute to the promotion of cancer [75]. These findings may also attest to the specific and sensitive nature of single-cell gel electrophoresis (“comet assay”) for detection of superior structural alignment of DES with the estrogen receptor and the resultant genomic disruption [76,77].

On considering the susceptibility of estrogen-sensitive cells to DNA damage, the present study implicates environmental estrogens in triggering the neoplastic process. In our study, MCF10A cells from benign human breast tumor underwent DNA damage without the influence of external stimuli. Addition of DES accelerated the production of DNA strand breaks at all doses. On addition of fig leaf extract to the growth medium, antioxidant constituents of the extract suppressed the DNA damage, thereby preventing the accumulation of DNA strand breaks at all dose levels. In contrast, Zhang and colleagues [69] used *Ficus carica* leaf extracts to suppress neoplastic cell survival, cell cycle and migration in triple-negative breast cancer MDA-MB-231 cells. Besides our reported finings, no other attempt to utilize a *Ficus carica* leaf extract to target the initiation stage of human breast cancer development in non-transformed, human breast epithelial cells was found. Successful
Ficus carica L. chemoprevention was evidenced by the inhibition and/or reversal of DNA damage (DNA strand breaks) and the apparent promotion of DNA repair following exposure of MCF10A cells to the first synthetic estrogen known to man.

Conclusion

Diethylstilbestrol, the first synthetic estrogen with non-steroidal carcinogenic potential, has been shown to disrupt the genomic and morphological integrity of non-transformed (benign) human epithelial breast tumor (MCF10A) cells, causing extensive DNA damage (strand breaks and fragmentation) characteristic of the onset of cancer. Cellular metabolism of this carcinogen to its oxidative quinone intermediate (DESQ) was also potent to MCF10A cells.

The prospective contribution of phytoestrogens in alleviating the public health burden of breast cancer is gaining momentum. This pilot study specifically targeted the initiation stage of carcinogenesis, for which natural chemopreventive agents were unavailable in the open literature at the time of this study. From this research, we report that treatment with Ficus carica leaf extract inhibits spontaneous DNA damage and reverses non-steroidal estrogen (DES)-induced DNA strand breaks in individual, non-transformed (benign), human epithelial breast tumor cells (MCF10A). Ficus carica differentially promotes DNA repair and ameliorates comet formation due to the irreversible interaction of oxidative quinine metabolites of DES (DESQ) with the nuclear apparatus. To our knowledge, this is among the first studies to implicate Ficus carica leaf extract in having both a chemopreventive and cancer therapeutic role in early-stage breast cancer.

We, therefore, conclude that Ficus carica L. leaf extract is biologically reactive in vitro and interacts with the nuclear complex to abrogate DNA strand breaks in MCF10A cells in the presence or absence of diethylstilbestrol (DES) and its oxidative quinine metabolite, 4′,4″-diethylstilbestrol quinine (DESQ).

Acknowledgment

The author is appreciative to Dr. Ronald D. Thomas (posthumous) for entrusting this work into her hands. This research was supported in part by NIH grants RR08111 and RR03020. All listed authors have contributed to the conception, experimental design and launch of this research. Significant contributions by the first author included: data acquisition (scoring the comets), data quality assessment, statistical analysis, and data interpretation; literature review; development of the intellectual content of this paper, drafting and editing the manuscript; as well as funding and submission for publication. We acknowledge lab technician, Alicia Tucker for invaluable training/support, as well as former lab members who may have worked on extract development. The ‘AACR Minority Scholar Award’ was presented to the author the first time this landmark research was presented at the 2007 AACR conference. The pilot study and enhanced literature review are presented here in honor of Dr. Ronald D. Thomas, who was for me an incredible mentor.

Abbreviations:

| Abbreviation | Description |
|--------------|-------------|
| SCGE         | Single-Cell Gel Electrophoresis |
| DES          | Diethylstilbestrol |
| DMSO         | Dimethylsulfoxide |
| DES-Q        | DES-4,4″-Quinone |
References

1. Xu J, Murphy SL, Kochanek KD, Bastian B, Di EA, et al. (2018) National Vital Statistics System. Deaths: Final data for 2016. National Vital Statistics Reports 67: 1–76.
2. World Life Expectancy. Cancer State Rankings. Accessed online on 17 September 2018.
3. Centers for Disease Control & Prevention, National Center for Health Statistics, National Vital Statistics System 2017 Ten leading causes of death by age group, United States – 2016. Atlanta, GA.
4. Florida Department of Health (2017) Florida Morbidity Statistics Report 2016. Section 8 – Cancer Surveillance.
5. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394–424. [PubMed: 30207593]
6. American Cancer Society 2018 Breast cancer facts and figures – 2017-2018. Atlanta, GA: American Cancer Society, Inc 2017.
7. Surveillance, Epidemiology and End Results (SEER) Program, SEER 9 Registries, National Cancer Institute, 2017 Breast cancer. Accessed 17 September 2018.
8. National Institutes of Cancer 2017 Breast cancer.
9. Block G (1992) The Data Support a Role for Antioxidants in Reducing Cancer Risk. Nutr Rev 50:207–213. [PubMed: 1641203]
10. Radiological Society of North America, Inc. (RSNA), 2018 Mammography may increase breast cancer risk in some high-risk women: News from the RSNA 2009 Annual Meeting.
11. Sporn MB, Suh N (2000) Chemoprevention of cancer. Carcinogenesis 21: 525–530. [PubMed: 10688873]
12. Sporn MB, Suh N (2002) Chemoprevention: An essential approach to controlling cancer. Nat Rev Cancer 2: 537–543. [PubMed: 12094240]
13. Marderosian D, Kratz AH, Riedlinger JE (2000) Complementary and alternative medical health care In Gennaro AR Remington: The Science and Practice of Pharmacy. 20th Edition Baltimore, MD: Lippincott Williams & Wilkins 1762–1764.
14. Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Can 3: 768–780.
15. Vinson JA (1999) The functional food properties of Figs. Cereal Foods World 44: 82–87.
16. United States Department of Agriculture (USDA), Natural Resource Conservation Service (NRCS), 2008 PLANTS Database. National Plant Data Team, Greensboro, NC.
17. United States Department of Agriculture (USDA), Economic Research Service (ERS), 2018b Export and Import Data – 2018.
18. United States Department of Agriculture (USDA), Natural Resource Conservation Service (NRCS), 2018c PLANTS Database. National Plant Data Team, Greensboro, NC.
19. North American Association of Central Cancer Registries (NAACCR) 2017 NAACCR fast stats: U.S. regions.
20. National Agricultura I Statistics Service (NASS) 2018 Figs – statistics. Accessed 17 September 2018.
21. Agricultural Marketing Resource Center (AgMRC), 2018 Commodities & Products: Figs. Accessed 17 September 2018.
22. Buchman DD (1996). Herbal Medicine. New York, NY: Wings Books.
23. Jellin JM, Gregory PJ, Batz F, Bonakdar R, Marshall J. et al. (2009) Pharmacist’s Letter/ Prescriber’s Letter - Natural Medicines Comprehensive Database, 11th Edition Stockton, CA: Therapeutic Research Faculty 648–649.
24. Duke JA (1997). The Green Pharmacy. New York, NY: Rodale Inc 453.
25. Goor A (1965) The history of the fig in the Holy Land from ancient times to the present day. Econ Bot 19: 124–135.
26. United States Department of Agriculture (USDA), Agricultural Research Service (ARS), 2018a National Nutrient Database for Standard Reference Legacy release Basic Report: 09089, Figs, raw.
27. Badgujar SB, Patel VV, Bandivdekar AH, Mahajan RT (2014) Traditional uses, phytochemistry and pharmacology of *Ficus carica*: A review. Pharm Biol 52: 1487–1503. [PubMed: 25017517]

28. O’Brien TG, Kinniar MF, Silver SC (1998) What’s so special about figs? Nature 392: 668–668.

29. Mawa S, Husain K, Jantan I (2013) *Ficus carica* L. (Moraceae): Phytochemistry, traditional uses, and biological activities. Evidence-based Complementary and Alternative Medicine 2013: 1–8.

30. Cassidy A, Franz M, Rimm EB (2016) Dietary flavonoid intake and incidence of erectile dysfunction. Am J Clin Nut 103: 534–541.

31. Bouyahya A, Bensaid M, Bakri Y, Dakka N (2016) Phytochemistry and ethnopharmacology of *Ficus carica*. Intl J Biochem Res 14: 1–12.

32. Steward WP, Brown K (2013) Cancer chemoprevention: A rapidly evolving field. Brit J Cancer 109: 1–7. [PubMed: 23736035]

33. Mehta RG, Murillo G, Naithani R, Peng X (2010) Cancer chemoprevention by natural products: How far have we come? Pharm Res 27: 950–961. [PubMed: 20238150]

34. Tawfik MS, Alhejy M (2014) Antioxidants in fig (*Ficus carica* L.) and their effects in the prevention of atherosclerosis in hamsters. J Food Nut Sci 2: 138.

35. Subash S, Essa MM, Al-Asmi A, Al-Adawi S, Vaishnav R, et al. (2014) Chronic dietary supplementation of 4% figs on the modification of oxidative stress in Alzheimer’s Disease Transgenic Mouse Model. BioMed Res Intl 2014: 1–8.

36. Al-Snafi AE (2017) Nutritional and pharmacological importance of *Ficus carica*: A review. IOSR J Pharm 7: 33–48.

37. Fraser C (2014) Ten incredible health benefits of figs.

38. Greuter MJ, Jansen-van der Weide MC, Jacobi CE, Osterwijk JC, Jansen L, et al. (2010) The validation of simulation model incorporation radiation risk for mammography breast cancer screening in women with a hereditary-increased breast cancer risk. Eur J Cancer 46: 495–504. [PubMed: 19945279]

39. Jansen-van der Weide MC, Greuter MJ, Jansen L, Oosterwijk JC, Pijnappel RM, et al. (2010) Exposure to low-dose radiation and the risk of breast cancer among women with a familial or genetic predisposition: A meta-analysis. Eur Radiol 20: 2547–2556. [PubMed: 20582702]

40. Joe BN, Sickles EA (2014) The evolution of breast imaging: past to present. Radiology 273: S23–S44. [PubMed: 25340437]

41. Sardanelli F, Fallenberg EM, Clauster P, Trimbolet RM, Camps-Herrero J, et al. (2016) Mammography: An update of EUSOBI recommendations on information for women. Insights into Imaging 8: 11–18. [PubMed: 27854006]

42. Caumo F, Romanucci G, Hunter K, Zorzi M, Brunelli S, et al. (2018). Comparison of breast cancers detected in the Verona screening program following transition to digital breast tomosynthesis screening with cancers detected at digital mammography screening. Breast Cancer Research and Treatment 170: 391–397. [PubMed: 29557996]

43. Weber B, Hayes J, Evans WP (2018) Breast density and the importance of supplemental screening. Current Breast cancer Reports 10: 122–130.

44. Rafferty EA, Park JM, Philpott LE, Poplack SP, Sumkin JH, et al. (2013). Assessing radiologist performance using combined digital mammography and breast tomosynthesis compared with digital mammography alone: Results of a multicenter, multi-reader trial. Radiology 266: 104–113. [PubMed: 23169790]

45. Obi N, Gornyk D, Heinz J, Vrielang A, Seibold P, et al. (2014) Determinants of newly diagnosed comorbidities among breast cancer survivors. J Cancer Survivorship 8: 384–393.

46. Darby S, McGale P, Taylor CW, Peto RP (2005) Longterm mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. The Lancet (Oncology) 6: 557–565. [PubMed: 16054566]

47. Obi N, Eulenburg C, Seibold P, Elieber U, Thone K, et al. (2018) Associations between adjuvant radiotherapy and different causes of death in a German breast cancer cohort. The Breast 38: 75–80. [PubMed: 29248876]

48. Bouillon K, Haddy N, Delaloge S, Garbay JR, Garsi JP, et al. (2011) Longterm cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol 57: 445–452. [PubMed: 21251585]

*J Bioequivalence Bioavailab*. Author manuscript; available in PMC 2019 December 06.
49. Russo J, Russo IH (2000) Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplasia 5: 187–200. [PubMed: 11149572]
50. Sporn MB, Dunlop NM, Newton DL, Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35: 1332–1338. [PubMed: 770206]
51. Sporn MB (1976) Vitamin A and its analogs (retinoids) in cancer prevention. Curr Concepts Nutr 6: 119–130.
52. Klaunig JE, Kamendulis LM (2010) Chemical carcinogenesis. 2nd Ed, McGraw-Hill Medical, San Francisco Pp: 109–120.
53. Olive PL, Banath JP (2006) The comet assay: A method to measure DNA damage in individual cells. Nat Protocol 1: 23–29.
54. Agabeili RA, Kasimova TE (2005) Anti-mutagenic activity of Armoracia rusticana, Zea mays and Ficus carica plant extracts and their mixture. Tsitol Genet 39: 75–79.
55. Carmichael PL, Mills JJ, Campbell M, Basu M, Caldwell J (2001) Mechanisms of hormonal carcinogenesis in the p53+/− hemizygous knockout mouse: Studies with diethylstilbestrol. Toxicol Pathol 29: 155–160. [PubMed: 11695552]
56. Melnick RL, Kohn MC, Portier CJ (1996) Implications for risk assessment of suggested non-genotoxic mechanisms of chemical carcinogenesis. Environ Health Perspect 104: 123–134. [PubMed: 8722116]
57. Hall JM, Couse JF, Korach KS (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276: 36869–36872. [PubMed: 11459850]
58. Levin ER, Petras RJ (2008) Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 108: 351–361. [PubMed: 17592774]
59. Turner AV, Kustrin SA, Glass BD (2007) Molecular aspects of phytoestrogen selective binding at estrogen receptors. J Pharm Sci 96: 1879–1885. [PubMed: 17518366]
60. Zhao E, Mu Q (2011) Phytoestrogen biological actions on mammalian reproductive system and cancer gland. Sci Pharm 79: 1–20. [PubMed: 21617769]
61. Chrzan BG, Bradford PG (2007) Phytoestrogens activates estrogen receptor beta-1 and estrogenic responses in human breast and bone cancer cell lines. Mol Nutr Food Res 51: 171–177. [PubMed: 17266178]
62. Mense SM, Remotti F, Bhan A, Singh B, El-Tamer M, et al. (2008) Estrogen-induced breast cancer alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol Appl Pharmacol 232: 78–85. [PubMed: 18640140]
63. Yasuda MT, Sakakibara H, Shimoi K (2017) Estrogen- and stress-induced DNA damage in breast cancer and chemoprevention with dietary flavinoid. Genes Environ 39: 10–18. [PubMed: 28163803]
64. Hankinson SE, Eliassen AH (2007) Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer. J Steroid Biochem Mol Biol 106: 24–30. [PubMed: 17719770]
65. Aghel N, Kalantari H, Rezaazadeh S (2011) Hepatoprotective effect of Ficus carica leaf extract in mice intoxicated with carbon tetrachloride. Iran J Pharm Res 10: 63–68. [PubMed: 24363682]
66. Márquez SR, Hernández H, Flores JA, Gutiérrez M, Duarte G, et al. (2012) Effects of Phytoestrogens on mammalian reproductive physiology. Tropical Subtropical Agroecosystems 15: S129–S145.
67. Oliveira AP, Valentao P, Pereiva JA, Silva BM, Tavares F, et al. (2009) Ficus carica L.: Metabolic and biological screening. Food Chem Tox 47: 2841–2846.
68. Lansky EP, Paavilainen HM, Pawlus AD, Newman RA (2008) Ficus spp. (fig): Ethnobotany and potential as anticancer and anti-inflammatory agents. J Ethnopharmacol 119: 195–213. [PubMed: 18639620]
69. Zhang Y, Wan Y, Hoo B, Li B, Jin Y, et al. (2018) Extracts and components of Ficus carica leaves suppress survival, cell cycle, and migration of triple-negative breast cancer MDA-MB-231 cells. Onco Targets and Therapy 11: 4377–4386.
70. Farooq A (2015) Structural and functional diversity of estrogen receptor ligands. Curr Top Med Chem 15: 1372–1384. [PubMed: 25866274]
71. Korach KS, Metzler M, McLachlan JA (1978) Estrogenic activity in vivo and in vitro of some diethylstilbestrol metabolites and analogs. Proc Nat’l Acad Sciences 75: 468–471.

72. Liehr JG, DaGue BB, Ballatore AM, Henkin J (1983) Diethylstilbestrol (DES) quinine: A reactive intermediate in DES metabolism. Biochem Pharmacol 32: 3711–3718. [PubMed: 6661246]

73. Liehr JG, DaGue BB, Ballatore AM (1985) Reactivity of 4’,4’’-diethylstilbestrol quinine, a metabolic intermediate of diethylstilbestrol. Carcinogenesis 6: 829–836. [PubMed: 4006069]

74. Chae K, Lindzey J, McLachlan JA, Korach KS (1998) Estrogen-dependent gene regulation by an oxidative metabolite of diethylstilbestrol, diethylstilbestrol-4’,4’’-quinone. Steroids 63: 149–157. [PubMed: 9558716]

75. Korach KS, McLachlan JA (1985) The role of estrogen receptor in diethylstilbestrol toxicity. Arch Toxicol Suppl 8: 33–42. [PubMed: 3913404]

76. Fairbairn DW, Olive PL, O’Neill KL (1995) The comet assay: A comprehensive review. Mutat Res 339: 37–59. [PubMed: 7877644]

77. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, et al. (2000) Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35: 206–221. [PubMed: 10737956]
Figure 1:
Stages of breast cancer development. Progression of breast cancer in females over four medically recognized stages: Stage 0 (early diagnosis of localized malignancy in breast ducts or milk glands); Stage 1 (cancer dislodges and can invade healthy, intact tissue such as fatty breast tissue, or to a lesser extent, lymph nodes); Stage 2 (onset of cancer growth, spread or both); Stage 3 (cancer is more resistant to treatment but has not contacted bones or organs); Stage 4 (cancer has metastasized from breast and lymph to other parts of body). Figure adapted from http://www.arimedex.com.
Figure 2:
Stepwise COMET assay procedure. The multistep process begins with cell growth and treatment. Suspended cells are fixed to slides prior to alkaline lysis, unwinding and electrophoresis. Neutralized slides can be stored in the refrigerator and away light until imaging is necessary. Slide are individually stained with propidium iodide immediately before fluorescence imaging and comet scoring.
Figure 3:
Comet profiles of MCF10A cells in the presence or absence of stimulus. Sample gallery of comets representing DNA strand breaks, fragmentation, and migration of fragments.
Figure 4:
Metabolism of Diethylstilbestrol. Conversion of DES to the highly active metabolite, DES-quinone (DES-Q) is a potent initiator of mutations in the DNA structure that cause cancer.
Figure 5:
Chemically-induced DNA Damage in Benign Human Breast Epithelial (MCF10A) Cells as Measured by Comet Assay.
Effects of DES, fig extract, or combined treatments on MCF10A cells. Induction or attenuation of DNA damage in human breast epithelial (MCF10A) cells with DES (0.1 – 10 μM), fig extract (5 – 15 μL), or high-dose DES plus fig combinations for up to 6 h.
NoTrtCtrl = No treatment control; DMSOCtrl = Dimethyl sulfoxide preserved control; DES = Diethylstilbestrol; FIG = Ficus carica leaf extract; DES-1, DES-10, DES-100 = DES 1, 10, and 100 μM, respectively; FIG-5, FIG-10, FIG-15 = FIG 5, 10, and 15 μL, respectively.
* Compared to DMSO control, p<.05
+ Compared to DES-10, p<.05
Δ Compared to DES-1, p<.05
# Compared to DES-100, p<.05
▼ Compared to DES 100-Fig 10
Table 1:
Effect of diethylstilbestrol (DES), a xenoestrogen, and its quinone metabolite on human breast epithelial cell (MCF10A) DNA integrity.

| Treatment   | ID | n   | Mean ± SEM  |  | N   | Mean ± SEM  |
|-------------|----|-----|-------------|---|-----|-------------|
|             |    | 40  | 0.863 ± 0.169 |  | 120 | 0.813 ± 0.090 |
| NoTrtCtrl   | 1a | 40  | 0.817 ± 0.165 |  | 120 | 0.759 ± 0.132 |
|             | 1b | 40  | 0.707 ± 0.114 |  | 120 | 0.680 ± 0.068 |
| DMSO Ctrl   | 2a | 40  | 0.767 ± 0.109 |  | 120 | 0.568 ± 0.132 |
|             | 2b | 40  | 0.703 ± 0.067 |  | 120 | 0.608 ± 0.246 |
| DES-1 µM    | 3a | 40  | 0.754 ± 0.257 |  | 120 | 0.715 ± 0.144 |
|             | 3b | 40  | 0.574 ± 0.111 |  | 120 | 0.574 ± 0.142 |
| DES-10 µM   | 4a | 40  | 0.715 ± 0.055 |  | 120 | 0.649 ± 0.066 |
|             | 4b | 40  | 0.559 ± 0.065 |  | 120 | 0.550 ± 0.079 |
| DES-100 µM  | 5a | 40  | 0.574 ± 0.067 |  | 120 | 0.550 ± 0.066 |
|             | 5b | 40  | 0.459 ± 0.065 |  | 120 | 0.576 ± 0.055 |
| DESQ-1 µM   | 6a | 40  | 0.574 ± 0.111 |  | 120 | 0.574 ± 0.142 |
|             | 6b | 40  | 0.559 ± 0.122 |  | 120 | 0.576 ± 0.055 |
| DESQ-10 µM  | 7a | 40  | 0.574 ± 0.067 |  | 120 | 0.574 ± 0.142 |
|             | 7b | 40  | 0.559 ± 0.065 |  | 120 | 0.576 ± 0.055 |
| DESQ-100 µM | 8a | 40  | 0.574 ± 0.067 |  | 120 | 0.574 ± 0.142 |
Table 2:
Effect of fig (*Ficus carica*) leaf extract on diethy stilbestrol (DES)-induced in human breast epithelial cell (MCF10A) DNA integrity.

| Treatment ID | n | Mean ± SEM | N | Mean ± SEM |
|--------------|---|------------|---|------------|
| FIG-5 µL     |   |            |   |            |
| 9a           | 40| 0.949 ± 0.256 | 120| 0.707 ± 0.093 |
| 9b           | 40| 0.547 ± 0.074 |   |            |
| 9c           | 40| 0.624 ± 0.080 |   |            |
| FIG-10 µL    |   |            |   |            |
| 10a          | 40| 0.739 ± 0.117 | 120| 0.685 ± 0.059 |
| 10b          | 40| 0.720 ± 0.098 |   |            |
| 10c          | 40| 0.597 ± 0.094 |   |            |
| FIG-15 µL    |   |            |   |            |
| 11a          | 40| 0.965 ± 0.160 | 120| 0.786 ± 0.082 |
| 11b          | 40| 0.751 ± 0.156 |   |            |
| 11c          | 40| 0.643 ± 0.099 |   |            |
| DES100+FIG5  |   |            |   |            |
| 12a          | 40| 1.013 ± 0.244 | 120| 1.013 ± 0.104 |
| 12b          | 40| 1.233 ± 0.171 |   |            |
| 12c          | 40| 0.793 ± 0.093 |   |            |
| DES100+FIG10 |   |            |   |            |
| 13a          | 40| 0.487 ± 0.066 | 120| 0.516 ± 0.042 |
| 13b          | 40| 0.561 ± 0.089 |   |            |
| 13c          | 40| 0.502 ± 0.060 |   |            |
| DES100+FIG15 |   |            |   |            |
| 14a          | 40| 0.537 ± 0.075 | 80 | 0.631 ± 0.066 |
| 14b          | 40| 0.802 ± 0.119 |   |            |
| DESQ10+FIG5  |   |            |   |            |
| 15a          | 40| 0.554 ± 0.075 | 120| 0.663 ± 0.055 |
| 15b          | 40| 0.594 ± 0.094 |   |            |
| 15c          | 40| 0.842 ± 0.111 |   |            |
| DESQ10+FIG10 |   |            |   |            |
| 16a          | 40| 0.807 ± 0.127 | 120| 0.715 ± 0.067 |
| 16b          | 40| 0.833 ± 0.130 |   |            |
| 16c          | 40| 0.505 ± 0.079 |   |            |
| DESQ10+FIG15 |   |            |   |            |
| 17a          | 40| 0.495 ± 0.096 | 120| 0.587 ± 0.058 |
| 17b          | 40| 0.686 ± 0.092 |   |            |
### Olive Tail Moment (OTM)

| By Slide | By Treatment Group |
|----------|--------------------|
|          |                   |
| Treatment | ID | n  | Mean | SEM  | N  | Mean | SEM |
|          | 17b | 40 | 0.581 | ± 0.111 |     |      |     |